Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL572706 | 0.86 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL22624018 | 0.85 | HPGD (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL2625518 | 0.85 | HPGD (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL3570460 | 0.84 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL30875141 | 0.84 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL15764147 | 0.83 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL13801217 | 0.83 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL16759817 | 0.83 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL15764146 | 0.83 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL12035619 | 0.83 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230055250-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-8513263-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8450322-B2 | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-7994164-B2 | Mineralocorticoid receptor antagonists and methods of use | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2011-07-07 | — | — | US | disclosed |
| US-20110112111-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-12 | — | — | US | disclosed |
| US-20100210618-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | US | disclosed |
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | NR1H2 1513/4885USP2 2629/4885SMN1; SMN2 11/4885 |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | BTK, SYK, LYN | NR1H2 3219/4885USP2 3791/4885SMN1; SMN2 2303/4885 |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | PDXK, DTYMK, TNNI3K | NR1H2 1395/4885USP2 4331/4885SMN1; SMN2 1553/4885 |
| US-20230055250-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K5, MAP4K1 | NR1H2 1974/4885USP2 3367/4885SMN1; SMN2 2995/4885 |
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | NR3C2, MC2R, REN | NR1H2 87/4885USP2 4790/4885SMN1; SMN2 2828/4885 |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | NTRK1, NTRK3, NTRK2 | NR1H2 1226/4885USP2 3593/4885SMN1; SMN2 844/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | NR1H2 176/4885USP2 3121/4885SMN1; SMN2 4086/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | NR1H2 1513/4885USP2 2629/4885SMN1; SMN2 11/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | NR1H2 1096/4885USP2 2164/4885SMN1; SMN2 3555/4885 |
| US-20100210618-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, NAT1 | NR1H2 205/4885USP2 4576/4885SMN1; SMN2 4358/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | NR1H2 3897/4885USP2 3555/4885SMN1; SMN2 3315/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | NR1H2 1096/4885USP2 2164/4885SMN1; SMN2 3555/4885 |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | NR1H2 2447/4885USP2 3807/4885SMN1; SMN2 1874/4885 |
| US-20110112111-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | NR1H2 38/4885USP2 3999/4885SMN1; SMN2 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.